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Activation of membrane-bound proteins and 
receptor systems: a link between tissue kallikrein 
and the KLK-related peptidases
Abstract: The 15 members of the kallikrein-related ser-
ine peptidase (KLK) family have diverse tissue-specific 
expression profiles and roles in a range of cellular pro-
cesses, including proliferation, migration, invasion, dif-
ferentiation, inflammation and angiogenesis that are 
required in both normal physiology as well as pathologi-
cal conditions. These roles require cleavage of a range 
of substrates, including extracellular matrix proteins, 
growth factors, cytokines as well as other proteinases. In 
addition, it has been clear since the earliest days of KLK 
research that cleavage of cell surface substrates is also 
essential in a range of KLK-mediated cellular processes 
where these peptidases are essentially acting as agonists 
and antagonists. In this review we focus on these KLK-reg-
ulated cell surface receptor systems including bradykinin 
receptors, proteinase-activated receptors, as well as the 
plasminogen activator, ephrins and their receptors, and 
hepatocyte growth factor/Met receptor systems and other 
plasma membrane proteins. From this analysis it is clear 
that in many physiological and pathological settings KLKs 
have the potential to regulate multiple receptor systems 
simultaneously; an important issue when these pepti-
dases and substrates are targeted in disease.
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Introduction
Tissue kallikrein or kallikrein 1 (KLK1/KLK1) was the first 
described member of a gene family located at human chro-
mosome 19q13.4 that encodes 15 serine proteinases named 
kallikrein-related peptidases (KLKs) (Gan et  al., 2000; 
Harvey et  al., 2000; Yousef and Diamandis, 2001). The 
action of KLK1, the archetypal member of this family, was 
first recognised over 100 years ago in the work of Abelous 
and Bardier who discovered that an alcohol-insoluble frac-
tion of human urine caused peripheral vasodilation and 
hypotension in dogs (Abelous and Bardier, 1909). Later 
studies showed that the hypotensive effect occurs, at least 
in part, by the action on bradykinin receptors, a sub-family 
of G protein-coupled receptors, of kinin peptides released 
from kininogens by KLK1 (Werle, 1934; Rocha e Silva et al., 
1949; Bhoola et  al., 1992). Notably, it became clear from 
the earliest days of research on the extended KLK family 
that these KLK1-related secreted extracellular peptidases 
also can have important physiological and pathological 
effects via actions on cell surface proteins. As summarised 
in Figure 1 and Table 1, it is now clear that these effects 
can occur both indirectly, for example by processing of 
precursor ligands as is the case of KLK1 cleavage of kini-
nogens; and directly, for example by proteolysis of cell 
surface proteins as has been reported also to occur when 
bradykinin receptors are cleaved by KLK1. This theme has 
certainly been borne out for other members of the KLK 
family with many examples reported over the last 20 years 
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of KLK-mediated phenotypes that require activation of 
cell surface receptor systems. In the following sections we 
summarise these findings with a particular focus on brady-
kinin receptors, proteinase-activated receptors, as well as 
the plasminogen activator and hepatocyte growth factor/
Met receptor systems and other cell surface proteins.
Kallikrein-kinin system
More than 100 years ago, Abelous and Bardier began to 
elucidate an important signalling pathway that has come 
to be known as the kallikrein-kinin system. The activat-
ing enzymes for this system are plasma kallikrein and 
tissue kallikrein, which are derived from two unrelated 
genes (Clements, 2000). The focus of this review is tissue 
kallikrein or KLK1. Tissue kallikrein (KLK1), the founding 
member of the kallikrein-related peptidase (KLK) family 
(Kraut et  al., 1930), is a glycoprotein with trypsin-like 
substrate specificity for cleavage after arginine (Arg) and 
lysine (Lys) residues. It is expressed in a range of tissues 
and organs, and can process kininogens, growth factors, 
and extracellular matrix (ECM) molecules to regulate 
inflammation and pain, blood vessel dilation and perme-
ability, blood pressure and sodium homeostasis control, 
kidney, heart and neurological function (Fiedler, 1979; 
Schachter, 1979; Brady et  al., 1989; Clements, 2000; 
Chao et  al., 2006; Madeddu et  al., 2007; Savvatis et  al., 
2010; Rhaleb et al., 2011; Stadnicki, 2011; Viel and Buck, 
2011; Kayashima et al., 2012; Regoli et al., 2012; da Costa 
et  al., 2014). As an extracellular peptidase, KLK1 exerts 
these pleotropic biological effects by cleavage of the sub-
strate, low molecular weight (LMW) kininogen, generat-
ing the kinin, lys-bradykinin, which exerts its biological 
functions via binding to the G protein-coupled receptor, 
the bradykinin B2 (Marcondes and Antunes, 2005). The 
related bradykinin B1 receptor is predominantly activated 
by a cleaved degradation product of lys-bradykinin at its 
C-terminal Arg by kininase I, lys-des-arg-bradykinin. The 
B1 receptor is largely an inducible receptor up-regulated 
in inflammatory conditions and tissue injury; conversely, 
the B2 receptor is constitutively expressed in a diverse 
range of healthy tissues mediating the action of kinins 
as well as up-regulated in disease (Madeddu et al., 2007; 
Savvatis et al., 2010; Stadnicki 2011; Viel and Buck, 2011; 
Kayashima et  al., 2012; Regoli et  al., 2012). KLK1 also 
directly induces rat uterine contraction and cardio-pro-
tection independent of kinin formation (Chao et al., 1981, 
2008), further suggesting KLK1 has potential biological 
functions by acting on other substrates in addition to 
kininogen. A recent study showed that migration of cir-
culating proangiogenic cells induced by KLK1 may not be 
all mediated by kinin in vitro while kinins are involved 
in the function of KLK1 in vivo (Spinetti et  al., 2011). Of 
particular interest to this review, the human bradykinin 
B2 receptor can be activated in kininogen-free systems 
in which cells are exposed to KLK1 and trypsin, but the 
direct cleavage of the B2 receptor to generate a signal has 
yet to be observed (Hecquet et al., 2000; Biyashev et al., 
2006). It thus remains to be seen if the B2 receptor can be 
considered as a ‘proteolytically-activated receptor’ akin 
to the proteinase-activated receptors (PARs), which are 
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Figure 1 Schematic diagram showing KLKs 1, 2 and 4-8 activatation of receptors and/or membrane-bound factors initiating their down-
stream signalling pathways.
BK, bradykinin; BKR, bradykinin receptors 1 and 2; CDCP1, CUB domain containing protein; HGF(A), hepatocyte growth factor (activator); KG, 
kininogen; KLK1, tissue kallikrein; PAR, proteinase-activated receptor; uPA(R), urokinase plasminogen activator (receptor). 
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activated by a proteolytically-unmasked tethered ligand 
(Adams et  al., 2011). These data have for the first time 
shown that a KLK peptidase could activate a membrane-
bound receptor and led the way for many of the studies 
described below.
Proteinase-activated receptors
PARs are G protein-coupled receptors – PAR1 to PAR4 – 
that are activated by proteolysis primarily mediated by 
serine proteinases with trypsin-like specificity for cleav-
age after Arg and Lys, including members of the KLK 
family (Vu et al., 1991; Bohm et al., 1996; Ishihara et al., 
1997; Xu et al., 1998; Boire et al., 2005; Vesey et al., 2007) 
as shown diagrammatically for KLK1 and KLK4 in Figure 1. 
These proteolytic agonists remove the PAR extracellular 
amino terminal pro-domain, unmasking a neo-epitope, 
termed the tethered ligand, that binds intramolecularly to 
induce intracellular signal transduction. Via these mecha-
nisms, PARs function as plasma membrane sensors of 
extracellular and cell surface associated proteinases that 
regulate cellular responses such as proliferation, migra-
tion, inflammatory responses, thrombus formation and 
angiogenesis, and contribute extensively to homeostasis 
as well as to disease progression (Macfarlane et al., 2001; 
Adams et al., 2011).
Proteolytic activation of human PAR1, occurring 
on the carboxyl side of residue Arg41, can be mediated 
by KLK1 (Gao et  al., 2010a,b), KLK4 (Mize et  al., 2008; 
Ramsay et al., 2008; Gratio et al., 2010), and KLK5, 6 and 
14 (Oikonomopoulou et  al., 2006). Similarly, PAR2 acti-
vation after Arg36 can occur through proteolysis by KLK2 
(Mize et al., 2008), KLK4 (Mize et al., 2008; Ramsay et al., 
2008), KLK5, KLK6 (Oikonomopoulou et  al., 2006) and 
KLK14 (Oikonomopoulou et al., 2006; Gratio et al., 2010), 
while PAR4 activation by cleavage following Arg47 can be 
carried out by KLK14 (Oikonomopoulou et al., 2006). Con-
sistently, another study demonstrated that while KLK6 
is able to efficiently cleave a peptide spanning the PAR2 
activation site, this proteinase could not cleave peptides 
spanning PAR1, PAR3 or PAR4 activation sites (Angelo 
et al., 2006). Interestingly, apart from thrombin no other 
PAR3 targeting proteinases have been identified (Ishihara 
et al., 1997). It is also important to note that KLKs can func-
tion as PAR antagonists by cleavage at sites other than the 
canonical activation site, leading to receptor inactivation 
or so-called ‘disarming’ (Adams et al., 2011). For example, 
KLK1 can disarm PAR1 (Gao et al., 2010a,b) and KLK14 can 
inactivate both PAR1 and PAR4 (Oikonomopoulou et al., 
2006).
Table 1 Summary of activation of cell membrane proteins and receptors by KLKs.
Kallikreins   Membrane proteins/receptors and signalling systems   References
KLK1   Kininogen: KLK1-(brady)kinin system   (Marcondes and Antunes, 2005)
  (Brady)kinin receptor (BKR)2   (Biyashev et al., 2006)
  PAR1: PAR1-PKC-Src-MMP, keratinocyte migration; 
migration of prostate cancer cells
  (Gao et al., 2010a)
(Gao et al., 2010b)
  BKR2, migration of circulating proangiogenic cells   (Spinetti et al., 2011)
KLK2   uPA   (Frenette et al., 1997)
KLK4   PAR1, PAR2,   (Mize et al., 2008; Ramsay et al., 2008; Gratio et al., 2010)
  uPA-uPAR   (Takayama et al., 2001; Beaufort et al., 2006)
  pro-meprin β   (Becker-Pauly et al., 2007; Ohler et al., 2010)
  EphB4   (This review)
  HGF/MET   (Mukai et al., 2008)
  CDCP1   This review
KLK5   Pro-HGFA   (Mukai et al., 2008)
  PAR2   (Stefansson et al., 2008)
  Desmoglein 1, cell-cell junction in oral squamous cancer   (Jiang et al., 2011)
KLK6   Amyloid precursor protein (APP) in Alzheimer’s disease 
and Parkinson’s disease;
  (Little et al., 1997; Ogawa et al., 2000; Magklara et al., 2003)
  PAR1, PAR2, PAR4   (Oikonomopoulou et al., 2006)
KLK7   Desmocollin, corneodesmosin;   (Caubet et al., 2004)
E-cadherin (Johnson et al., 2007)
  uPAR   (Ramani and Haun, 2008a)
KLK8   rPAR2 but not hPAR2   (Stefansson et al., 2008; Ramachandran et al., 2012)
KLK14   PAR2   (Stefansson et al., 2008; Gratio et al., 2011; Chung et al., 2012)
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In terms of the functional consequences of KLK acti-
vation of PARs, several studies have demonstrated that 
these mechanisms regulate important cellular responses 
in both physiological and pathological settings. For 
example, KLK1 promotes keratinocyte proliferation and 
migration in vitro and in an in vivo rat skin wound healing 
model via a PAR1 dependent, BKR2 independent mecha-
nism requiring downstream activation of PKC and Src 
resulting in increased matrix metalloproteinase activ-
ity (MMP) and regulation of EGFR signalling (Gao et al., 
2010a). This group has also recently shown that KLK1, via 
PAR1, promotes migration and invasion of prostate cancer 
DU145 but not lung cancer A549 cells (Gao et al., 2010b). 
Signalling via this PAR and PAR2 induced by both KLK2 
and KLK4 enhanced proliferation of prostate cancer DU145 
cells (Mize et al., 2008). Interestingly, using murine whole 
splenocyte preparations and the human Jurkat T cell line it 
has been shown that KLK6 via PAR1 promotes pro-survival 
and inhibits pro-apoptotic mechanisms, leading to vigor-
ous splenic T cell survival in the presence of the cell death 
inducing agents, camptothecin, dexamethasone, stau-
rosporine and Fas-ligand (Scarisbrick et  al., 2011). This 
KLK can also initiate intracellular signalling in neurons 
via PAR1 and in astrocytes through both PAR1 and PAR2 
(Vandell et  al., 2008) and has recently been reported to 
serve as a molecular trigger via PAR1 of processes involved 
in development of astrogliosis (Scarisbrick et al., 2012a). 
In addition, use of function blocking antibodies and phar-
macological approaches demonstrated that KLK4 acti-
vates PAR1 but not PAR2 in colon cancer cells with PAR1 
signalling promoting migration of these cells via ERK1/2 
(Gratio et  al., 2010). In contrast, KLK14 signals to HT29 
colon cancer cells via PAR2 leading to receptor internali-
zation and proliferation (Gratio et al., 2011). It is also note-
worthy that KLK4, secreted by prostate cancer epithelia, 
can activate PAR1 in surrounding stroma to initiate release 
of the cytokine interleukin-6 that stimulates cancer cell 
proliferation in a paracrine loop (Wang et al., 2009).
Hepatocyte growth factor/Met 
receptor system
Hepatocyte growth factor (HGF) and its receptor MET are 
required for normal development and homeostasis while 
aberrant activation of this receptor system, via overex-
pression, mutation or dysfunctional ligand production 
and/or activation, contributes to malignant transforma-
tion and progression of a variety of cancers. In addition, 
these changes can often be associated with poor patient 
outcome and drug resistance (Trusolino et  al., 2010). In 
its precursor state as pro-HGF, the presence of the pro-
domain prevents activation of Met signalling. This pro-
domain is released by the action of the Arg/Lys-specific 
serine proteinase HGF activator (HGFA), which itself must 
be converted from zymogen (pro-HGFA) to active enzyme 
by other serine proteinases such as thrombin (Mahtouk 
et al., 2010). In addition to this thrombin/HGFA/HGF Met 
receptor activating cascade, it appears that members of 
the KLK family can also initiate signalling via this receptor 
system through at least two levels as shown diagrammati-
cally for KLK4 in Figure 1. The first level is via activation of 
pro-HGFA as it has recently been demonstrated that KLK4 
and KLK5, but not KLK2 or KLK3, activate this zymogen at 
its canonical activation site Arg407 (Mukai et  al., 2008). 
Importantly, KLK4 and KLK5 activated HGFA efficiently 
activated pro-HGF and induced cell scattering and inva-
sion in vitro while these actions were strongly inhibited by 
HGFA inhibitor, a type 1, integral membrane Kunitz-type 
serine protease inhibitor that inhibits HGFA and other pro-
HGF-activating proteases (Mukai et al., 2008). KLK-medi-
ated regulation of this signalling cascade is also possible 
at the level of pro-HGF activation as it has been shown that 
KLK4 is able to activate urokinase-type plasminogen acti-
vator (Takayama et al., 2001) which is an efficient activator 
of pro-HGF (Naldini et al., 1992; Mars et al., 1993).
Plasminogen activator system
The plasminogen activator system is involved in cancer 
progression and metastasis through various processes, 
such as cell migration, adhesion and cell cycle regulation. 
Urokinase-type plasminogen activator (uPA) is a serine 
protease and its receptor uPAR (CD87) is a three domain 
(D1D2D3) glycoprotein tethered to the cell membrane with 
a GPI anchor (Huai et al., 2006). Expression of uPA-uPAR 
has been associated with prognosis in different cancers, 
although cleaved uPAR has stronger association with 
clinical outcome of patients than those with intact forms 
(Reuning et  al., 2003; Rasch et  al., 2008). For example, 
expression of uPAR lacking D1 predicted a poor progno-
sis in the patients with squamous cell lung cancer (Almasi 
et al., 2005), suggesting that the cleavage of this receptor 
has a role in cancer progression. KLK2, KLK4, and KLK8 
can activate uPA (Frenette et  al., 1997; Takayama et  al., 
2001; Rajapakse et al., 2005; Beaufort et al., 2006). Indeed, 
the first identified substrate of KLK4 was uPA (Takayama 
et al., 2001), which can also activate the metalloprotease 
(MMP) system via plasmin (Schmalfeldt et al., 2001; Smith 
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and Marshall, 2010), further linking these three proteo-
lytic systems. Interestingly, a later study that examined 
the proteolytic effects of KLK4 at different concentrations 
(Beaufort et  al., 2006) demonstrated that low levels of 
KLK4 cleaved uPA while higher KLK4 levels also had an 
effect on its receptor, uPAR (see Figure 1). This latter pro-
teolytic action generates a soluble D1 fragment and D2D3 
fragment still bound to the cell membrane. Beaufort et al. 
(2006) also showed that KLK4 cleaved uPAR on the mem-
brane of U937 monocytes led to a reduced binding capacity 
to uPA. It is known that uPAR interacts with integrins and 
the ECM protein vitronectin (Smith and Marshall, 2010), 
and the function of the cell membrane-bound uPAR D2D3 
domain is in binding to these adhesive proteins, promot-
ing migration of cells and cancer progression. Interest-
ingly, KLK7 is also suggested to play a role in the shedding 
of uPAR generating a soluble form of this receptor and 
reduced pancreatic cancer cell adhesion to vitronectin 
(Ramani and Haun, 2008b). Similar cell biology effects 
of the proteolytic action of KLK2, KLK4 and KLK8 on uPA-
uPAR remain to be studied. Indeed, more in depth studies 
of the mechanisms involving these two protease systems 
are required to fully understand their interactive roles in 
human diseases.
EphB4 and its ligand ephrin-B2
The Eph receptor tyrosine kinases are the largest family of 
receptor tyrosine kinases with 14 members in two subfam-
ilies designated A and B (Arvanitis and Davy, 2012). Eph 
receptors are involved in many cellular and developmen-
tal processes including development, homeostasis and 
disease (Bush and Soriano, 2012). Several Eph receptors 
are also over-expressed in cancer and novel anti-cancer 
strategies that target these proteins are in development 
(Nievergall et al., 2012; Boyd et al., 2014). EphB4, in par-
ticular, is commonly over-expressed in most epithelial 
cancers, including 66% of prostate cancers (PCa), 58% 
of breast cancers and 86% of ovarian cancers (Lee et al., 
2005; Xia et  al., 2005; Kumar et  al., 2006; Kumar et  al., 
2007; Brantley-Sieders et al., 2011).
The ligands to Eph receptors are called ephrins and 
they too are divided into two subfamilies – ephrin-A and 
ephrin-B – based on sequence homologies and interac-
tions with Eph receptors (Arvanitis and Davy, 2012). In 
contrast to most other ligands of receptor tyrosine kinases, 
ephrins are also membrane-bound on the outside of cells 
– ephrin-A ligands via glycosphosphatidylinositol (GPI) 
links and ephrin-B with a single transmembrane domain. 
Despite significant promiscuity between other Eph family 
members and the ephrin ligands, the single physiolog-
ically-relevant ligand of the EphB4 receptor is ephrin-B2 
(Pasquale, 2004). In a similar manner to the classical 
trans-signalling pathways of Eph-ephrins, forward sig-
nalling, through EphB4, and reverse signalling, through 
ephrin-B2, requires heterotetramerisation of two receptors 
(on cell 1) and two ligands (on cell 2). This normal interac-
tion between EphB4 and ephrin-B2, requires direct cell-
cell contact and induces tumour suppression in the EphB4 
expressing cell and stabilization of cell-cell adhesion and 
stimulation of angiogenesis through the ligand express-
ing cell (Chen et al., 2008; Pasquale, 2010). Disruption of 
cell-cell junctions or changes in the Eph-ephrin balance 
(through the overexpression of EphB4), both of which can 
occur in cancer cells, prevents or diminishes ligand-recep-
tor interaction and allows the clustering of EphB4 and 
the use of ligand-independent signalling pathways that 
promote tumour formation. It has also been reported that 
Eph receptors and ephrins when co-expressed in neurons 
and cancer cells can engage in lateral cis associations, 
which lessen receptor activation through trans-signalling 
(Hornberger et al., 1999; Yin et al., 2004; Carvalho et al., 
2006; Kao and Kania, 2011; Falivelli et al., 2013).
High affinity trans-signalling interactions between 
Eph receptors and ephrin ligands are terminated by two 
key mechanisms. In the first of these, the whole receptor-
ligand complex is endocytosed into either cell via a mecha-
nism that is dependent on Rac signalling and may include 
pinching off part of the plasma membrane of the opposite 
cell (Marston et al., 2003; Zimmer et al., 2003; Pitulescu 
and Adams, 2010). The second mechanism involves pro-
tease cleavage of the ligand or the EphR after formation 
of the receptor-ligand complex. Proteases linked to Eph 
receptor and ephrin proteins include RHBDL2, a rhom-
boid transmembrane serine protease that cleaves ephrin-
B3, several matrix metalloproteinases and A Disintegrin 
and Metalloproteases (ADAMs) that have been reported to 
cleave both Eph receptors and ephrins, including ephrin-
A2 and ephrin-B1 (Hattori et al., 2000; Pascall and Brown, 
2004; Litterst et al., 2007; Tanaka et al., 2007; Lin et al., 
2008; Inoue et al., 2009; Janes et al., 2009). Using indirect 
‘gain of function’ approaches, EphB4 has been implicated 
as a potential substrate for ADAM-8, -9 and -17 (Janes 
et  al., 2005; Guaiquil et  al., 2009; Guaiquil et  al., 2010; 
Mendelson et al., 2010; Weskamp et al., 2010).
More recently, we have identified EphB4 and its ephrin-
B2 ligand as biochemical substrates of KLK4 (Lisle et al., 
2013). An in silico approach was used to identify poten-
tial KLK4 cleavage sites through mapping the consensus 
KLK4 cleavage site to accessible epitopes on the surface 
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of proteins from protein databases, for which there were 
defined crystal structures. Ephrin-B2 was confirmed as a 
substrate of KLK4 by incubation of recombinant proteins 
in various molar ratios, and the primary cleavage site in 
ephrin-B2 confirmed using N-terminal sequencing as after 
R174 (NP_004084). Closely related kallikreins KLK3 (PSA), 
KLK2 and KLK4 can cleave ephrin-B2 and we have used a 
concentration of KLK peptidase at  > 4 μg/ml that is under 
the physiological range as the PSA  concentration is 100–
2000 μg/ml in normal male seminal fluid (Lovgren et al., 
1999; Drabovich et  al., 2011) while KLK2 is 2–20  μg/ml 
(Lovgren et al., 1999) and KLK4 is 0.2–202 μg/ml (Obiezu 
et al., 2005; Shaw and Diamandis, 2007).
Although EphB4 was not identified as a potential 
KLK4-substrate using the in silico approach (because a 
suitable crystal structure was not available), in parallel 
experiments recombinant EphB4 was also shown to be 
cleaved by recombinant KLK4 (Figure 2). The KLK4 cleav-
age site in EphB4 was identified by N-terminal sequenc-
ing and is in the extracellular domain between R508 
and A509. Cleavage after R508 would release almost the 
complete extracellular domain of EphB4 and this was 
confirmed by addition of recombinant KLK4 to cells 
expressing surface EphB4 with subsequent identification 
of the cleaved ectodomain fragment of the predicted size 
via Western blot analysis. In addition, a protein band of 
the predicted size of the cleaved ectodomain was identi-
fied in cell lysates from EphB4+/KLK4+ prostate cancer 
cells, confirming that cleavage of the ectodomain can 
occur in a biological setting. Interestingly, this cleavage 
event appears to precede a second cleavage event cata-
lysed by the presenilin-dependent protease γ-secretase, 
which releases the intracellular part of EphB4 from the 
membrane. This mechanism – ectodomain shedding fol-
lowed by release of an intracellular fragment, is common 
to many receptor tyrosine kinases and in many cases the 
released fragments have important biological functions 
(Stephenson et al., 2012). The biological consequences of 
these two EphB4 cleavage events, and the functions of the 
released fragments, are currently being explored in clini-
cal prostate cancer samples and cell lines.
CUB-domain containing protein 1 
(CDCP1)
In the last few years the cell surface glycoprotein CUB-
domain containing protein 1 (CDCP1) has emerged as a 
novel substrate of serine proteinases that have Arg/Lys 
trypsin-like substrate specificity (He et al., 2010), includ-
ing, potentially, those members of the KLK family that 
cleave after these amino acids, such as KLKs 1, 2, 4–6, 8, 
10–14. However, it is not known if CDCP1 can be cleaved 
by those with chymotryptic-like specificity, i.e., KLKs 3, 
7 9, or with some cross chymotryptic substrate specific-
ity. CDCP1, also known as SIMA135 (Hooper et al., 2003), 
gp140 (Brown et al., 2004), Trask (Bhatt et al., 2005) and 
CD318 (Wortmann et  al., 2009), is an 836 amino acid 
single pass transmembrane glycoprotein that consists of 
extracellular and intracellular domains encompassing 
approximately 660 and 150 residues respectively. Serine 
proteinase-mediated cleavage occurs within the extra-
cellular domain at adjacent sites, Arg368 and Lys369, to 
initiate Src-mediated phosphorylation of CDCP1 at tyros-
ine (Y) 734, Y743 and Y762 and binding of phospho(p)-Src 
and another kinase p-PKCδ (He et  al., 2010). Recently it 
has been shown that serine proteinase-mediated cleavage 
of CDCP1 promotes the survival of disseminating cancer 
cells as they escape from blood vessels. Increased cancer 
cell dissemination occurs via a p-Src/p-PKCδ mechansism 
that initiates p-Akt pro-survival and anti-apoptotic path-
ways (Casar et al., 2012). CDCP1 is up-regulated in cancers 
of the lung, kidney, ovary and pancreas where its elevated 
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Figure 2 (A) Silver stained PAGE showing KLK4 cleavage of full 
length EphB4 extracellular domain tagged with IgG Fc tag (EphB4-
ecd-Fc) at a ratio of active KLK4 to EphB4 of 1:10 (0.1), 1:100 (0.01) 
and 1:5,000 (0.005). The EphB4-ecd-Fc fragment generated by 
KLK4 activity is indicated by a red box. (B) Diagram showing KLK4 
cleavage of human EphB4 releases an ectodomain (70 kDa) from 
the cell surface and leaves an intracellular membrane-tethered 
fragment (50 kDa). This cleavage is then followed by hydrolysis by 
γ-secretase releasing an intracellular domain (ICD) of 47 kDa.
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Figure 3 (A) Anti-CDCP1 and -GAPDH Western blotting of lysates 
from HeLa-CDCP1 cells incubated with KLK4 (50 nm) at 37°C for 1, 
6 and 24 h. Full-length (135 kDa) and cleaved (70 kDa) CDCP1 are 
indicated. (B) Schematic showing that KLK4 cleavage of full length 
CDCP1 generates a 70 kDa form.
expression is associated with poor patient outcomes 
(Awakura et al., 2008; Ikeda et al., 2009; Miyazawa et al., 
2010; Razorenova et al., 2011; Dong et al., 2012). As CDCP1 
is widely expressed in mammalian epithelia including 
these cancers of epithelial origin where elevated KLK 
expression is also commonly observed (Lawrence et  al., 
2010), we were interested to see if members of this family 
are able to cleave CDCP1. In our hands, low levels of KLK4 
were able to induce CDCP1 cleavage within 6 h, generating 
a 70 kDa fragment (Figure 3A), with the schematic shown 
in Figure 3B, although the function of this cleaved product 
remains to be investigated. These data suggest that in set-
tings where active KLK4 or other Arg/Lys-specific KLKs are 
present, CDCP1 may act as a plasma membrane substrate 
to transduce signals across the cell surface including that 
promoting cell survival.
CDCP1 is known to be cleaved by matriptase and 
trypsin, which also cleave PAR2 (Brown et  al., 2004; He 
et al., 2010) but it is thought that the endogenous protease 
is plasmin as it was found to be necessary and sufficient 
to cleave CDCP1 in vivo and plasminogen knockout mice 
lacked cleavage of CDCP1 in lung tissue (Casar et al., 2012). 
Increasingly, the expression of protease activated recep-
tors and other proteolytically-activated proteins such as 
CDCP1 is becoming more clinically significant as potential 
markers of disease progression and as molecular targets. 
For example up-regulation and aberrant expression of 
both CDCP1 and uPAR are correlated with a poorer prog-
nosis and can be indicative of disease progression in some 
cancer types (Awakura et al., 2008; Ikeda et al., 2009; Ma 
and Tao, 2012). Furthermore, as plasmin is generated from 
plasminogen by uPA it is possible that CDCP1 and other 
protease activated receptors could be implicated in the 
same pathway, contributing to dissemination and metas-
tasis of invading tumour cells and therefore could repre-
sent multiple targets within a common pathway. As we 
noted for the HGF/Met activation and uPA/uPAR cascades, 
it appears likely that KLKs will also be able to contribute 
to activation of CDCP1 signalling at multiple levels as it 
has recently been shown that plasmin is the crucial serine 
protease executing in vivo cleavage of this receptor during 
cancer cell dissemination in mice (Casar et al., 2012).
Other cell membrane-bound 
proteins as KLK substrates
In addition to the above receptor systems, there are a range 
of other associated cell surface proteins that are cleaved by 
members of the KLK family. For example, KLK6 can hydro-
lyse amyloid precursor protein (APP), which is localized in 
senile plaques and neurofilament tangles in the brain of 
Alzheimer’s disease (AD) patients and is important in the 
deposition of amyloid plaques during progression of this 
disease (Little et  al., 1997; Ogawa et  al., 2000; Magklara 
et  al., 2003). Also, KLK6 is able to cleave myelin basic 
protein (MBP) in oligodendrocytes and Schwann cells in 
the central nerve system, which is related to demyelinat-
ing diseases such as multiple sclerosis (Scarisbrick et al., 
2012b). Although KLK5 and KLK7 have been localised in 
numerous tissues their function has been extensively elu-
cidated in keratinization, stratum corneum formation, 
turnover and desquamation of the skin. This occurs via 
the hydrolysis and degradation of cell membrane-bound 
adhesion glycoproteins, such as corneodesmosin, desmo-
collin 1 and plakoglobin (Caubet et al., 2004).
The cadherin proteins, desmogleins (DSGs), are key 
factors in desmosome formation and cell integrity in 
particular in skin (Amagai and Stanley, 2012), and loss 
of them has also been associated with cancer progres-
sion (Thiery and Sleeman, 2006). DSG2 is a substrate of 
KLK7 and transfection of this peptidase significantly up-
regulated levels of soluble DSG2 fragments in culture 
media from pancreatic cancer BxPC-3 cells (Ramani et al., 
2008c). Interestingly, using siRNA knockdown and pro-
tease inhibition approaches, cleavage of DSG1 by KLK5 
was induced in oral squamous cancer SCC25 cells where 
decreased aggregation of these cells was seen (Jiang et al., 
2011). It is known that the cell-cell contact protein, E-cad-
herin, plays a critical role in cell integrity and loss or deg-
radation of this molecule has been associated with cancer 
progression (Thiery and Sleeman, 2006). Of note, adding 
KLK7 into pancreatic cancer BxPC-3 cells generated more 
soluble E-cadherin fragments while the aggregation of 
these cells significantly decreased, but invasion increased 
(Johnson et al., 2007). These data suggest a role of these 
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KLK peptidases in the progression of cancer by hydrolysis 
of cell adhesion proteins.
Meprins are members of the astacin metalloprotease 
family and have α and β subunits originally identified 
on the apical brush or plasma membrane of epithelial 
cells (Bond et  al., 2005). Their unique localization and 
proteomic activity have been associated with trafficking 
of host cells such as, macrophage or metastatic cancer 
cells (Bond et al., 2005). A recent study using a terminal 
amine isotopic labeling of substrates (TAILS) approach 
identified that pro-KLK7 is a substrate of meprin α and β 
in the conditioned media from keratinocyte HaCaT cells 
(Jefferson et  al., 2012) supporting their function in skin 
epithelial cells. Interestingly, both meprin α and β sub-
units were localized in the plasma membrane of HaCaT 
keratinocytes and pro-meprin β was cleaved by KLK4 
(Becker-Pauly et  al., 2007; Ohler et  al., 2010), further 
suggesting a complex interaction between these two pro-
tease families.
Conclusion
Here we have summarised the current knowledge on the 
hydrolysis of cell membrane receptors/proteins by KLK1 
and other KLK peptidases (Table 1) and their initiation 
of downstream signalling pathways. Although there is a 
diversity of tissue specificity and expression of these pro-
teases, we have identified a strong association between 
the classical membrane-bound receptor activation func-
tion of KLK1 and similar attributes of other more recently 
discovered members of the KLK family. In addition, it is 
notable that there is increasing evidence of complex pro-
teolytic cascades between the KLKs, uPA/uPAR and met-
alloproteinase families. A better understanding of these 
interactive cascades and downstream cellular signalling 
pathways initiated by these peptidases will help to fully 
elucidate the biological functions and pathophysiological 
role of KLKs in vivo.
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